TAGCyx Biotechnologies

29/06/2026

on June 30th, CEO, Chizuko Koseki will give a pitch talk at 「Nakanoshima Qross Global Life Sciences Cluster KICK-OFF EVENT - NQ Global Life Sciences Startup & Investment Connect -」
The details can be found below.

未来医療国際拠点「Nakanoshima Qross（中之島クロス、以下「NQ」）」を運営する一般財団法人未来医療推進機構（大阪市北区、理事長：澤芳樹）は、国内外のVC／CVC／事業会社が集う国際的なライフサイエンス投資コミュニティ...

07/05/2026

We are pleased to announce that our research on the development of an apheresis treatment for preeclampsia has been accepted and published in Science Reports. Title: Selective removal of soluble FLT-1 using a high-affinity DNA aptamer for potential apheresis treatment of preeclampsia. Authors: Kensuke Owari, Haishun Piao, Miyuki Hori, Kazunobu Futami
https://www.nature.com/articles/s41598-026-50826-2
We are eager to develop the efficacious treatment for preeclampsia patients.

Preeclampsia (PE) is a pregnancy-specific hypertensive disorder that has been associated with elevated levels of soluble fms-like tyrosine kinase-1 (sFLT-1), which is thought to contribute to impaired angiogenesis by binding and neutralizing angiogenic factors such as Vascular Endothelial Growth Fac...

27/03/2026

Our CEO, Chizuko Koseki had an interview with Tokyo University IPC venture capital.
The article is seen here.

独自の基盤技術で核酸アプタマー（※）を創出し、薬品に活用することで、次世代の新薬モダリティ（治療手段）に取り組んでいるタグシクス・バイオ株式会社。抗体医薬と同様に、標的タンパク質へ特異的に作用するアプ...

04/02/2026

2月20日に弊社代表の古関が、、第17回次世代モダリティセミナー ～核酸アプタマー医薬品の可能性～のイベントにて講演をいたします。
https://www.link-j.org/event/article-50420.html #:~:text=%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9%E3%83%A9%E3%83%B3%E3%82%AD%E3%83%B3%E3%82%B0%20%C2%B7%201.%20MEDISO%E3%82%BB%E3%83%9F%E3%83%8A%E3%83%BC%E3%82%B7%E3%83%AA%E3%83%BC%E3%82%BA%EF%BD%9E%E5%8C%BB%E7%99%82%E7%B3%BB%E3%83%99%E3%83%B3%E3%83%81%E3%83%A3%E3%83%BC%E3%81%AE%E5%A3%81%E3%82%92%E8%B6%85%E3%81%88%E3%82%8B%EF%BD%9E%20vol.20.%E4%BA%8B%E6%A5%AD%E8%A8%88%E7%94%BB%E7%B7%A8%EF%BC%9A%E5%9F%BA%E7%A4%8E%E3%81%8B%E3%82%89%E5%A7%8B%E3%82%81%E3%82%8BTPP%E3%81%A5%E3%81%8F%E3%82%8A%E3%81%AE%E9%81%93%E3%81%97%E3%82%8B%E3%81%B9%20%C2%B7%202.

28/01/2026

We have entered into an alliance with FRONTEO which has an unique proprietary Drug Discovery AI platform. Please see press release here.

タグシクス・バイオは革新的な新規人工塩基対技術を用いた創薬プラットフォーム技術によってDNAアプタマーを創出します。抗体に続く次世代の新薬モダリティであり、私達は効果が高くかつ安全性の高い医薬品を、安価に...